Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnly, idempotent, openWorld and non-destructive, so the safety profile is covered. The description adds genuinely non-redundant behavior: $0.01 USDC per successful x402 call on Solana, an equivalent HTTPS endpoint, and the FDA disclaimer being embedded in the response. It doesn't mention rate limits or failure/refund behavior, which keeps it from a 5.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Is the description appropriately sized, front-loaded, and free of redundancy?

Content is front-loaded — capabilities first, disclaimer and pricing/endpoint last. The long parenthetical list of label sections is dense but each item earns its place by clarifying the 'sections' parameter. One sentence carrying three capabilities is slightly heavy but not padded.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With six optional params, no output schema, and rich annotations, the description does the right work: it describes what comes back (label sections, serious-event counts with top reactions, recall class and reason) and warns about the disclaimer. An agent could call this correctly without opening further docs; only fine-grained response shape remains unspecified.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, so the baseline is 3, but the description adds real meaning: it names the concrete label sections available (boxed warning, indications, dosage, contraindications, warnings, adverse reactions, interactions, any SPL field) and specifies that 'top reported reactions' is what limit controls. That exceeds what the terse schema strings convey.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Does the description clearly state what the tool does and how it differs from similar tools?

Names a specific resource (FDA drug facts by brand/generic name or NDC) and enumerates the three payload classes: label sections, FAERS adverse-event totals, and enforcement recalls. It's clear what the tool returns, but it doesn't explicitly differentiate itself from the sibling fda_recalls / fda_adverse_events tools even though its scope overlaps with both.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Does the description explain when to use this tool, when not to, or what alternatives exist?

Usage is implied by the enumerated capabilities and the 'not for clinical use' caveat, but there is no explicit when-to-use guidance or statement of when to prefer fda_recalls or fda_adverse_events instead. The agent must infer routing from the description's content list alone.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.